Suramin as a chemosensitizer: Oral pharmacokinetics in rats

Pharmaceutical Research

Volumn 21, Issue 11, 2004, Pages 2058-2063

  Ogden, Adam ^a   Wientjes, M Guillaume ^a,b   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemosensitizer; Oral pharmacokinetics; Suramin

Indexed keywords

SURAMIN; TRACER; TRITIUM; ANTINEOPLASTIC AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENTEROHEPATIC CIRCULATION; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; ANIMAL; BIOAVAILABILITY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHYSICAL; INJECTIONS, INTRAVENOUS; MALE; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET; SURAMIN;

EID: 21644445750     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000048197.77546.75     Document Type: Article

References (44)

1. S. Song, M. G. Wientjes, Y. Gan, and J. L. Au. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad. Sci. USA 97:8658-8663 (2000).
2. S. Song, M. G. Wientjes, C. Walsh, and J. L. Au. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res. 61:6145-6150 (2001).
3. Y. Zhang, S. Song, F. Yang, J. L. Au, and M. G. Wientjes. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J. Pharmacol. Exp. Ther. 299:426-433 (2001).
4. S. Song, E. Hurh, B. Yu, M. Wientjes, and J. Au. Suramin enhances the in vivo antitumor activity of paclitaxel in human breast xenografts. Proc. Am. Assoc. Cancer Res. 43:5393 (2002).
5. B. Yu, S. Song, M. Wientjes, and J. Au. Suramin enhances activity of CPT-11 in human colorectal xenograft tumors. Proc. Am. Assoc. Cancer Res. 44:763 (2003).
6. Y. Xin, D. Chen, S. Song, G. Lyness, M. Wientjes, and J. Au. Low-dose suramin enhances antitumor activity of mitomycin C in bladder tumors. Proc. Am. Assoc. Cancer Res. 45:2002 (2004).
7. A. Ogden, S. Song, M. Wientjes, and J. Au. Nontoxic doses of suramin enhance the activity of gemcitabine and paclitaxel in pancreatic tumors. Proc. Am. Assoc. Cancer Res. 45:2148 (2004).
8. G. Lyness, S. Jang, Y. Gan, Y. Zhang, M. Wientjes, and J. Au. Fibroblast growth factors and chemoresistance in renal cell carcinomas. Proc. Am. Assoc. Cancer Res. 43:4718 (2002).
9. M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, A. J. Murgo, R. Jensen, T. K. Yeh, D. Chen, S. Song, M. Grever, and J. L. Au. Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) Patients. Lung Cancer 41:S149 (2003).
10. M. A. Villalona-Calero, M. G. Wientjes, G. A. Otterson, S. Kanter, D. Young, A. J. Murgo, B. Fischer, C. DeHoff, D. Chen, T. K. Yeh, S. Song, M. Grever, and J. L. Au. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 9:3303-3311 (2003).
11. J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, and D. H. Johnson. Comparison of Four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:92-98 (2002).
12. C. A. Stein. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53:2239-2248 (1993).
13. R. Dreicer, D. C. Smith, R. D. Williams, and W. A. See. Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest. New Drugs 17:183-186 (1999).
14. A. Falcone, A. Antonuzzo, R. Danesi, G. Allegrini, L. Monica, E. Pfanner, G. Masi, S. Ricci, M. Del Tacca, and P. Conte. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 86:470-476 (1999).
15. A. Falcone, E. Pfanner, I. Brunetti, G. Allegrini, M. Lencioni, C. Galli, G. Masi, R. Danesi, A. Antonuzzo, M. Del Tacca, and P. F. Conte. Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy. Tumori 84:666-668 (1998).
16. M. Hussain, E. I. Fisher, D. P. Petrylak, J. O'Connor, D. P. Wood, E. J. Small, M. A. Eisenberger, and E. D. Crawford. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a southwest oncology group study. J. Clin. Oncol. 18:1043-1049 (2000).
17. L. Miglietta, L. Canobbio, C. Granetto, M. O. Vannozzi, M. Esposito, and F. Boccardo. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. J. Cancer Res. Clin. Oncol. 123:407-410 (1997).
18. M. R. Mirza, E. Jakobsen, P. Pfeiffer, B. Lindebjerg-Clasen, J. Bergh, and C. Rose. Suramin in non-small cell lung cancer and advanced breast cancer - two parallel phase II studies. Acta Oncol. 36:171-174 (1997).
19. R. J. Motzer, E. Dmitrovsky, W. H. Miller Jr., W. P. Tong, D. F. Bajorin, H. I. Scher, and G. J. Bost. Suramin for germ cell tumors. in vitro growth inhibition and results of a phase II trial. Cancer 72:3313-3317 (1993).
20. B. L. Rapoport, G. Falkson, J. I. Raats, M. de Wet, B. P. Lotz, and H. C. Potgieter. Suramin in Combination with Mitomycin C in Hormone-Resistant Prostate Cancer. A Phase II Clinical Study. Ann. Oncol. 4:567-573 (1993).
21. L. M. Reyno, M. J. Egorin, M. A. Eisenberger, V. J. Sinibaldi, E. G. Zuhowski, and R. Sridhara. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J. Clin. Oncol. 13:2187-2195 (1995).
22. P. J. Rosen, E. F. Mendoza, E. M. Landaw, B. Mondino, M. C. Graves, J. H. McBride, P. Turcillo, J. deKernion, and A. Belldegrun, Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J. Clin. Oncol. 14:1626-1636 (1996).
23. L. Qiao, J. G. Pizzolo, and M. R. Melamed. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells. Biochem. Biophys. Res. Commun. 201:581-588 (1994).
24. S. P. Howard, S. J. Park, L. Hughes-Davies, C. N. Coleman, and B. D. Price. Suramin increases p53 protein levels but does not activate the p53-dependent g1 checkpoint. Clin. Cancer Res. 2:269-276 (1996).
25. S. T. Palayoor, E. A. Bump, B. A. Teicher, and C. N. Coleman. Apoptosis and clonogenic cell death in pc3 human prostate cancer cells after treatment with gamma radiation and suramin. Radiat. Res. 148:105-114 (1997).
26. M. A. Eisenberger and L. M. Reyno. Suramin. Cancer Treat. Rev. 20:259-273 (1994).
27. C. P. Chijioke, R. E. Umeh, A. U. Mbah, P. Nwonu, L. L. Fleckenstein, and P. O. Okonkwo. Clinical pharmacokinetics of suramin in patients with onchocerciasis. Eur. J. Clin. Pharmacol. 54:249-251 (1998).
28. J. M. Collins, R. W. Klecker Jr., R. Yarchoan, H. C. Lane, A. S. Fauci, R. R. Redfield, S. Broder, and C. E. Myers. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J. Clin. Pharmacol. 26:22-26 (1986).
29. R. J. Motzer, D. M. Nanus, P. O'Moore, H. I. Scher, D. F. Bajorin, V. Reuter, W. P. Tong, J. Iversen, C. Louison, and A. P. Albino. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. 52:5775-5779 (1992).
30. H. I. Scher, D. I. Jodrell, J. M. Iversen, T. Curley, W. Tong, M. J. Egorin, and A. Forrest. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52:64-70 (1992).
31. A. M. Westermann, R. Dubbelman, J. P. Baars, W. H. Moolenaar, J. H. Beijnen, and S. Rodenhuis. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemother. Pharmacol. 46:57-62 (2000).
32. T. E. Voogd, E. L. Vansterkenburg, J. Wilting, and L. H. Janssen. Recent research on the biological activity of suramin. Pharmacol. Rev. 45:177-203 (1993).
33. M. Kassack and P. Nickel. Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues. J. Chromatogr. B Biomed. Appl. 686:275-284 (1996).
34. R. Klecker and J. Collins. Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography. J. Liq. Chromatogr. 8:1685-1696 (1985).
35. K. Yamaoka, T. Nakagawa, and T. Uno. Application of akaike's information criterion (aic) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175 (1978).
36. W. P. McNally, P. D. DeHart, C. Lathia, and L. R. Whitfield. Distribution of [14C]suramin in tissues of male rats following a single intravenous dose. Life Sci. 67:1847-1857 (2000).
37. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
38. S. L. Bramer, M. G. Wientjes, and J. L. Au. Absorption of 2′,3′-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum. Pharm. Res. 10:763-770 (1993).
39. M. Kassack and P. Nickel. Stability of suramin in aqueous solution; possible implications for the search for suramin metabolites in patients. Arch. Pharm. (Weinheim) 329:225-228 (1996).
40. F. H. Martini. Fundamentals of Anatomy & Physiology, Prentice Hall, Englewood Cliffs, NJ, 1995.
41. J. J. Kettenes-van den Bosch, E. Hop, W. Overbeek, W. J. M. Underberg, J. H. Beijnen, and A. Bult. Degradation of suramin in aqueous solutions. Int. J. Pharm. 155:27-34 (1997).
42. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26 (2001).
43. J. M. Zamora, H. L. Pearce, and W. T. Beck. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454-462 (1988).
44. D. Chen, S. Song, T. K. Yeh, J. L. Au, M. Villalona-Calero, G. Otterson, S. Kanter, and M. G. Wientjes. Phase I Pharmacokinetics of suramin in combination with paclitaxel and carboplatin in non-small-cell lung cancer patients. AAPS Ann Mtg & Expo, AAPS PharmSci Supplement on CD-Rom. Vol 3 (supplement) (2001).